- Home
- REPL vs COGT Comparison
REPL vs COGT Comparison
Compare REPL & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- COGT
- Stock Information
- Founded
- REPL 2015
- COGT 2014
- Country
- REPL United States
- COGT United States
- Employees
- REPL N/A
- COGT N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- COGT Health Care
- Exchange
- REPL Nasdaq
- COGT Nasdaq
- Market Cap
- REPL 578.4M
- COGT 545.3M
- IPO Year
- REPL 2018
- COGT 2018
- Fundamental
- Price
- REPL $8.00
- COGT $4.37
- Analyst Decision
- REPL Strong Buy
- COGT Buy
- Analyst Count
- REPL 6
- COGT 7
- Target Price
- REPL $20.00
- COGT $14.17
- AVG Volume (30 Days)
- REPL 967.9K
- COGT 1.7M
- Earning Date
- REPL 05-15-2025
- COGT 05-06-2025
- Dividend Yield
- REPL N/A
- COGT N/A
- EPS Growth
- REPL N/A
- COGT N/A
- EPS
- REPL N/A
- COGT N/A
- Revenue
- REPL N/A
- COGT N/A
- Revenue This Year
- REPL $31.16
- COGT N/A
- Revenue Next Year
- REPL N/A
- COGT N/A
- P/E Ratio
- REPL N/A
- COGT N/A
- Revenue Growth
- REPL N/A
- COGT N/A
- 52 Week Low
- REPL $4.92
- COGT $3.72
- 52 Week High
- REPL $17.00
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- REPL 36.82
- COGT 34.56
- Support Level
- REPL $6.44
- COGT $4.12
- Resistance Level
- REPL $7.97
- COGT $5.09
- Average True Range (ATR)
- REPL 0.73
- COGT 0.54
- MACD
- REPL 0.08
- COGT -0.02
- Stochastic Oscillator
- REPL 41.47
- COGT 23.90
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.